Illustrative image.

Biktarvy

Name: Biktarvy
Brand: Gilead SI
Availability: InStock

Bictegravir, Emtrictabine, Tenofovir

Prescription required

$2142.00

50-200-25 · 3 × 30 tablets · 3 months supply

BrandBranded medicine· By Gilead SI

$714.00 per month

How long a supply?

1 month$714.00 a monthOne-off$714.00

3 months$714.00 a monthOne-off$2142.00

6 months$714.00 a monthOne-off$4284.00

Supplied from Turkey

Test mode: no payment is taken. View cart

Annual cost

$8568a year at this pack size

Prescription required

Upload your prescription after ordering, or send it to our pharmacy team. We dispense only against a valid prescription.

50-200-25

FDA boxed warningPost treatment acute exacerbation of hepatitis b

Severe acute exacerbations of hepatitis B have been reported in patients with HIV-1 and HBV who have discontinued products containing emtricitabine (FTC) and/or tenofovir disoproxil fumarate (TDF), and may occur with discontinuation of BIKTARVY.

Closely monitor hepatic function with both clinical and laboratory follow-up for at least several months in patients with HIV-1 and HBV who discontinue BIKTARVY. If appropriate, anti-hepatitis B therapy may be warranted.

Read this with the rest of the clinical information

About Biktarvy

Overview

Biktarvy is a combination tablet containing bictegravir, emtricitabine and tenofovir alafenamide. It is used as a complete treatment regimen for HIV-1 infection, with suitability depending on treatment history and drug resistance. Its ingredients work against HIV by blocking enzymes called integrase and reverse transcriptase.

What it treats

HIV-1 infection in adults and children weighing at least 14 kg, as a complete treatment regimen for those who: - Have not previously received antiretroviral treatment. - Have received treatment but do not have a suppressed viral load, with no known or suspected resistance to integrase inhibitors, emtricitabine or tenofovir. - Are switching from a stable antiretroviral regimen with a suppressed viral load (HIV-1 RNA below 50 copies/mL), with no known or suspected resistance to bictegravir or tenofovir.

Safety information

Side effects

Common side effects of Biktarvy include diarrhea, nausea and headache. Serious side effects that warrant contacting a doctor include severe flare-ups of hepatitis B, new or worsening kidney problems, and immune reconstitution syndrome, in which changes in the immune response may require further evaluation and treatment. Other serious risks include lactic acidosis (a buildup of lactic acid in the blood) and severe liver enlargement with fat buildup. The label directs treatment to be stopped if symptoms or test results suggest lactic acidosis or significant liver toxicity. Blood and urine tests are needed when starting treatment and during treatment as clinically appropriate to check kidney function.

FDA boxed warning

Post treatment acute exacerbation of hepatitis b

A boxed warning is the strongest warning the US Food and Drug Administration requires on a medicine label. Text is taken from the official label, with internal section references removed.

Before taking this medicine

Do not take Biktarvy with dofetilide or rifampin. Biktarvy can raise dofetilide levels, potentially causing serious or life-threatening effects. Rifampin can lower bictegravir levels, which may make Biktarvy less effective and lead to resistance. Biktarvy can cause new or worsening kidney problems. Kidney function and urine tests are needed before starting treatment and during treatment as appropriate. People with chronic kidney disease also need blood phosphorus monitoring. Immune reconstitution syndrome, a reaction involving the recovering immune system, may require further assessment and treatment. Treatment must be stopped if symptoms or test results suggest lactic acidosis (a build-up of lactic acid in the blood) or serious liver toxicity, including severe liver enlargement with fat accumulation. Biktarvy is not recommended for children weighing less than 14 kg.

Interactions

Biktarvy is a complete HIV-1 treatment regimen, so taking it with other antiretroviral medicines for HIV-1 is not recommended. Ask your doctor to review the full prescribing information for important drug interactions before and during treatment.

Using Biktarvy

Dosing

Dosing is set by your prescriber. Each health care professional may prescribe medication differently according to a patient's medical history and condition, so follow the directions on your prescription label and speak to your doctor or pharmacist before changing anything.

Storage

Store below 25°C in a dry place, in the original pack, away from direct light and moisture. Do not keep it in a bathroom. Keep all medicines out of the sight and reach of children.

Clinical information on this page is summarised from the US FDA label BIKTARVY (BICTEGRAVIR SODIUM, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE FUMARATE) TABLET [GILEAD SCIENCES, INC.] (DailyMed, retrieved 19 September 2026).

Patient information and references

Official and supporting information to read alongside advice from your prescriber or pharmacist.

Patient information leaflet (PDF)

Reviews

No reviews yet. Mail Order Drugs opened recently, and we publish reviews only from verified customers of this site, so this space stays empty until real ones arrive.